Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting

MDL-101 preclinical data support efficacy and safety of a differentiated precision medicine approach for LAMA2 Congenital Muscular Dystrophy


Preclinical data showing that our CRISPR-based... | April 19, 2023

Related Keywords

Los Angeles ,California ,United States ,Tokyo ,Japan ,Massachusetts ,Waltham ,Haru Morita ,Modalis Therapeutics Corporation Tokyo Stock Exchange ,Tokyo Stock Exchange Growth ,American Society Of Gene Cell Therapy ,Modalis Therapeutics Corporation ,Tokyo Stock Exchange ,Annual Meeting ,American Society ,Cell Therapy ,Muscular Dystrophy ,Modalis Therapeutics ,Advancing Epigenetic Editing ,Novel Muscle Tropic ,Deliver Promising Single Dose Treatment ,Late Breaking Abstracts ,Congenital Muscular Dystrophy ,Modalis Therapeutics Corporation Stock Exchange ,News ,Information ,Press Release ,Reclinical ,Data ,Support ,Efficacy ,End ,Safety ,F ,Differentiated ,Precision ,Medicine ,Approach ,Or ,Llama2 ,Congenital ,Muscular ,Dystrophy ,Showing ,Hat ,Ur 4883 Jp3922600006 ,